Showing posts with label gsk. Show all posts
Showing posts with label gsk. Show all posts

Friday, March 25, 2016

Analytical Controls in an Evolving Technology and Regulatory Landscape


 
IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Rachel Orr, Senior Scientist, GlaxoSmithKline R&D, United Kingdom for an exclusive interview that delves into analytical controls in an evolving technology and regulatory landscape, the topic of her presentation at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.


1. What key analytical challenges do oligonucleotide developers need to overcome in order to achieve regulatory approval?

Oligonucleotides are inherently difficult to analyze - they are neither traditional, small nor large molecules, and the techniques and well established methodologies for pharmaceutical analysis are all focused on these distinct classes. In addition, there is very limited regulatory guidance when it comes to oligonucleotides, so there are no set rules to follow. There are often discussions as to whether oligonucleotide analysis should follow small molecule rules and regulations or align with biopharmaceuticals; opinions are divided.

With limited experience across the industry in marketing applications it is difficult to assess what is needed in order to gain regulatory approval and this is one of the biggest challenges in CMC oligonucleotide development. There is no recent precedence of global oligonucleotide marketing applications and as such it is difficult to ascertain what may and may not be acceptable. Close engagement with the regulators is something which helps to form strategies and controls and hopefully this will increase the likelihood of success of regulatory approvals going forwards.


2. How have advancements in technology improved the analytical process? Can you provide examples?

Since the last successful oligonucleotide marketing application there have been considerable enhancements in technologies. UHPLC is now common throughout the industry and techniques such as high resolution NMR and mass spectrometry are much more affordable and quick. These advances in technology mean that the resolution and robustness of methodologies can be much improved, however has a downside that the regulators may well expect us to present them with these improvements by first intent.

Increased understanding of non "typical" molecules throughout the industry has enabled wider thinking and collaboration between different pharmaceutical companies, with more people working together on the problem progress will inevitably come quicker. As more people engage with the concept of oligos and as technology continues to evolve, I anticipate a large shift in the way we look to control oligonucleotides analytically in coming years.


3. What are the most common mistakes that oligonucleotide drug developers encounter during CMC submissions?

Again, due to there being so few oligonucleotides which have gone through the full CMC process I think it is difficult to make too many sweeping statements, however the key issues that I have come across all stem from attempting to fit oligonucleotides into a box. Whether it is the small molecule group or the biopharmaceutical groups who take on the challenge of oligonucleotides, it is generally only a few "experts" within that team who work on the molecules. It is impossible to fit existing small or large molecule platforms onto oligonucleotides and a lot of time, resources and money can be wasted trying to do so! Due to the small pool of people working on the oligo projects it can also be challenging when it comes to elements such as wider reviews of submissions as the reviewers are not always as well informed about the challenges associated with oligonucleotide analysis. Education of these reviewers and key stakeholders is an activity that cannot be underestimated in time or importance! This emphasizes the benefits of cross-pharmaceutical company collaborations.


Want to hear more from industry experts like Rachel? See our exclusive TIDES speaker Q&A series here.




Share this article with your social network, just click below to share now!


Thursday, September 24, 2015

Exclusive Interview with Dr. Ian Tomlinson of GlaxoSmithKline

As Senior Vice President and Head of Biopharmaceuticals R&D and Head of Biopharmaceuticals R&D and Worldwide Business Development (WWBD) at GlaxoSmithKline, Dr. Tomlinson combines the resources and development expertise of a large pharmaceutical company, with the entrepreneurial spirit of a smaller biotech organization, bringing early research, late-stage biopharm development and manufacturing expertise into one organization. He served as the Chief Scientific Officer and Executive Vice President of Domantis Inc., and Domantis Limited. Dr. Tomlinson co-founded Domantis Limited in 2000.

In this interview, listen to his views on antibody therapeutic development, shaped by his background both in large pharma and smaller biotech.


Ian Tomlinson is one of the scientific advisory board members and organizers of the Antibody Engineering & Therapeutics conference scheduled for December 7-10, 2015 in San Diego.

Download the event agenda now.

Register now with the code D15172BLOG and save $400!


Share this article with your social network, just click below to share now!


Tuesday, August 11, 2015

Antibody Repertoires - Past, Present and Future

IBC's Antibody Engineering & Therapeutics event taking place December 7-10 in San Diego is the #1 forum for academia and industry to connect for scientific exchange and networking in Antibody Engineerings & Therapeutics, Immunobiology and Next-Generation Binders. To give you a sneak peek at the high caliber of the content presented at the conference - we would like to give you FREE access to complete videos from some of the 2014 presentations.

 http://www.ibclifesciences.com/AntibodyEng/presentations.xml?utm_source=NMM&utm_medium=BL&utm_campaign=081115_BL_fullsessionaccessform#form

We hope to see you in San Diego this December!


Share this article with your social network, just click below to share now!


Monday, January 25, 2010

DDP 2010: DDP Event Kickoff Panel Discussion in Grand Ballroom: Enabling Drug Delivery technologies: Improving Current Therapies

Moderator: Lee Shorter, Director, Biophysical Sensors and Nanomaterials, GSK Pharmaceuticals
Robert A. Baughman, PharmD, PhD, Vice President, Experimental Pharmacology, Mannkind Corporation
Randolph M. Johnson, PhD,Vice President and Chief of Technology Development, Molecular and Integrative Pharmacology, KAI Pharmaceuticals, Inc.
Timothy S. Nelson, President and CEO, MAP Pharmaceuticals
Riccardo Panicucci, PhD, Global Head of Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research Inc.
Eric Tomlinson PhD, DSC, President and Chief Executive Officer, Altea Therapeutics Corporation
Mary Gardner, Director, Technology Assessment, Hospira, Inc.

As we move through 2010, what will be the effect of the US healthcare plan? There will be an increased and continued financial pressure on emerging biotech and drug delivery. Mergers and acquisitions will continue. Two companies that were major players just last year are no more. There will be a continued pressure of Pharma on the stock market.

The Panel discussion is now open. The first question they’re addressing is: What are some of the key developments from drug deliverers in technology platforms?
Rick: In the future, we’re not going to be able to rely on innovative molecules. Molecular innovations need to be coupled with innovative delivery technologies. It would be great for a platform to fit in as many of the platforms as possible.

Randy: What’s important form a small biotech’s perspective is the new opportunity for growth and differentiation. The convergence of new technologies with more new chemical entities can lead to success in the future. There is pricing restrictions and pressure on the Pharma industry, but the blockbuster could still come with new technologies coupled with chemical entities. If we have a enw drug delivery company, maybe they’ll go after a drug that’s already proven. There is a double risk when tehse two things are combined. The regulatory pathway may be a little different, but the merging of technologies could bring new blockbuster drug products to the market.

What is the current value for paring current molecules with new delivery methods?
Novartis: Just coming up with blockbusters is not a model going forward. They’re looking at patient-centric ways to move forward. They’re going to look at every good opportunity to find something new to get it into their pipeline across their network. They haven’t always thought this way. They need to have a few game changers that will change up the way they do business, and at the same time, they’re working on many exciting things that will change the way they do business.

How does a company address reimbursement issues for more costly technology?
-It has to be attached to patient outcomes. It has to cost less to treat patients effectively. We can better plan clinical trials, so overall, there is a benefit. And Pharma can subsequently getting reimbursed for those things.

Mary: It comes down to a cost/benefit analysis.

What are some of the new opportunities to the developer once one has already successfully transferred a drug to a new delivery platform?
-That drug delivery can be enabled. You can develop the product, it’s highly differentiated, the delivery system a higher degree of compliance, you can grow the market and the clinical use of the drug. There is an opportunity for price premium if there is a benefit.

What is the best time to partner on a new technology? When do you need to go to big Pharma?
Novartis wants to be part of the development process. For good technologies, they want to make sure they’ll get to the finish line together. Some in Pharma believe that can’t do that anymore, but, they are trying to be more like a biotech company. Their future depends on it. At Novartis, they believe that the earlier the better. It’s on a one by one basis, but if there is an opportunity, Novartis will work on making it a technology.

How can we show insulin you show inhaled insulin taken for a lifetime is safe without a clinical trial that takes a life time without a clinical trial that takes a lifetime?
You cannot demonstrate lifetime safety until you’ve had a lifetime. But there are techniques and probability that can change this. Your pulmonary system is constantly fighting off other systems, such as smoking and smog. If someone said that an effective lifetime use of inhaled insulin, we must do everything we can and use all appropriate models, and do a study for the safety of the product. We look at small segments to determine the safety. There is no guarantee, but use all available processes to make the assessment.


Share this article with your social network, just click below to share now!


Friday, January 22, 2010

2010 DDP Awards: Partnering Excellence Nominee: Eurand

Eurand is nominated for the Partnering Excellence based on a partnership deal that Troy Harmon did with GSK. In this alliance, Eurand created optimal value for the partnering by being very sensitive to the needs and required time lines of the partner. Extraordinary efforts were made by both parties to quickly negotiate the deal and by Eurand to quickly execute on the development plan. The product, Lamictal ODT, went from agreement signature to NDA submission in only 19 months! The entire process was highly iterative throughout development and the parties had extensive communication throughout to achieve excellent results in a very short timeline. The excellent relationship between the two companies is further supported by a recent panel at a 2009conference where the parties participated together in discussing the value of drug delivery partnerships.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.


Share this article with your social network, just click below to share now!


Monday, January 11, 2010

Join over 250 Biopharmaceutical Executives who will experience DDP in less than 3 weeks

Will you GAIN INSIGHTS from the top renowned thought leaders on leveraging drug delivery to maximize value?

*Merck Serono * Pfizer * Purdue Pharma * BMS * Bayer * Novartis * Ranbaxy Labs * GSK * Amgen * Genzyme * Mannkind Corporation * Eurand * Sandoz * Healthcare Futurists * Deutsche Bank * and 80 + more…

Will you EXPLORE in-person the latest cutting-edge drug delivery technologies and mechanisms?

*Nanotechnology * RNAi Delivery * Modified Release * Biosimilars * NanoCrystals * Laser Epidermals * Electronic Injection Devices * Pain Product Delivery * Antibodies * Transdermal Systems * Orals * Needle-free vs. Needle-Based Systems

Will you OBTAIN the newest industry strategies and information through top-level keynotes, case studies and panel discussions addressing what you need to know NOW?

*Pipelines * Partnerships * Patients * Policy * Profitability * Emerging Markets * Reform * Technology

Will you NETWORK with the world’s leading Pharma, Biotech and Drug Delivery companies?

3M Company * AAIPharma Services Corporation * Abbott Laboratories * Abraxis BioScience Inc * Ache Laboratorios Farmaceuticos * Adhesives Research Inc * Aisling Capital * Alkermes Inc * Allergan Inc * Altea Therapeutics * Amgen Inc * Amylin Pharmaceuticals Inc * Anchen Pharmaceuticals Inc * Antares Pharma * Aprecia Pharmaceuticals Company * Aradigm Corporation * Arch Life Sciences * Arecor Limited * Astellas Pharma * Atlantic Pharmaceuticals Inc * Aveva Drug Delivery Systems Inc * Bang & Olufsen Medicom AS * Banner Pharmacaps Inc * Baxter Healthcare Corporation * Bayer HealthCare * BD Horizons * BIND Biosciences Inc * Biogen Idec * Bioject Medical Technologies Inc * Bionumbers * Biotechnology Value Fund LP * Boston BioCom LLC * Bouty * Bristol Myers Squibb Company * Cambrex Corporation * Cambridge Consultants * Cambridge Consultants Inc * Camurus AB * CEDRA Corporation * Center for Health Value Innovation * Center for Medicine in Public Interest * ChemImage Corporation * Chiesi Farmaceutici SpA * Cigna * CIMA LABS * ComPan * CustomRx * Cydex Inc * Daniela Mavor * Davidson, Davidson & Kapple LLC * Depomed Inc * Deutsche Bank * Dharma Therapeutics * Dicerna Pharmaceuticals * Dow Corning Corporation * DPT Laboratories * DSM Biomedical * DSM Pharmaceutical Products Inc * Durect Corporation * EGEN Inc * ELAN Drug Delivery Incorporated * Elan Drug Technologies * Elcam Medical * Eli Lilly & Company * Emergent Technologies, Inc. * Endo Pharmaceuticals Inc * Eurand Inc * Flamel Technologies Inc * Flextronics * FMC Corporation * Future of Healthcare & the Changing Business Environment * Genentech Inc * Genzyme Corporation * Gerresheimer AG * GlaxoSmithKline Pharmaceuticals * Glide Pharma * Growthworks Capital Inc * H2A Associates * Halozyme Therapeutics Inc * Hannaford Brothers & Company * Haselmeier * Helvoet Pharma Inc * Henkel * Hospira Inc * INNERCAP Technologies Inc * Institut Rosell Inc * Insulet Corporation *
J S New * Janisys * Johnson & Johnson * Joyce Lonergan * KAI Pharmaceuticals Inc * Keystone Nano Inc * Labtec Gmbh * Landec Corporation * Lipocine Inc * Liquidia Technologies Inc * Losan Pharma GmbH * LTS Lohmann Therapy SystemsMadeira Therapeutics * MannKind Corporation *MAP Pharmaceuticals Inc * MedPhysion * MedTRACK * Merck & Company * Merck Serono SA * Merrion Pharmaceuticals * Mikron * Miller Tabak Co LLC * MIT * Mochida Seiyaku KK * MonoSol Rx * NexBio * Nissen Consulting Group, LLC * Northern Lipids Inc * Novartis * Noven Therapeutics LLC * Novo Nordisk * Oakwood Laboratories * Ocelus * Ompi of America * Orexo AB * Pacific Research * Palyon Corporation * Pantec Biosolutions AG * Pappas Ventures * Par Pharmaceutical Inc * Partners in Care * Partners Rx * Perfecseal * Pfeiffer & Valois Pharma * Pfizer Inc * Pharma Nueva Company Ltd * Pharmaceutics International Inc * PharmaCircle * Plantex USA Inc * PM360 * Prasco * Purdue Pharma LP * QPS LLC * Ranbaxy Labs Ltd * Ratio Inc * Receptor Therapeutics Inc * Regence Group * RXi Pharmaceuticals * Sandoz International GmbH * Sanofi Aventis Inc * SciDose LLC * Sofgen Pharmaceuticals * SR One * Supernus Pharmaceuticals Inc * SurModics Pharmaceuticals * SwissMedDev * Tablets & Capsules Inhalation Transdermal * Team Consulting Ltd * Technology Catalysts International * The Benfield Group * The Medical Pipeline * TransPharma Medical * Tris Pharma Inc * Unigene Laboratories Inc * Univ of California San Francisco * University of Connecticut * University of Illinois * University of Maryland * Unomedical AS * Upsher Smith Labs * URL Pharma * US FDA CDER * Valeo Partners * Vapotherm Inc * Vetter Pharma * Watson Pharmaceuticals * West Coast Clinical Trials LLC * Wildwood Ventures Ltd * Wyeth Research * Zogenix * Zosano Pharma

Will you MAKE your next deal?

As the leading drug delivery meeting place getting you closer to the next deal, Drug Delivery Partnerships is the one annual stop where you will experience the newest ideas, technologies and solutions for your business and pipeline needs. Can you get all of THAT in your office?

Register today to join the longest running and most respected drug delivery conference in the pharmaceutical industry.

The DDP exhibit hall is almost SOLD OUT! Only One Booth is Left! If this year’s attendance is any indicator, 2010 is going to be huge year for Drug Delivery. With over 80% pharmaceutical and biotech executives in attendance , we are outpacing 2009 and 2008. This is the ONE partnering event you can’t miss this year!

Register before January 8th and save $300 to maximize your event value and experience by making your key meetings and contacts now!

We look forward to seeing you in Orlando!


Share this article with your social network, just click below to share now!


Wednesday, December 9, 2009

Nabi Biopharma to Receive $5M from GSK

MSN Money reports that Nabi Biopharma is to receive a $5 million milestone payment from GlaxoSmithKline Biologicals Co as Nabi Biopharma announces the initiation of a Phase I/II clinical trial for two of the antigens in the PentaStaph vaccine candidate, which is now owned by GlaxoSmithKline Biologicals (GSK). As a result of the initiation of the trial, Nabi is eligible for and has invoiced GSK $5 million for successful completion of this milestone due under the agreement governing Nabi's sale of PentaStaph and related assets to GSK. This milestone payment was contingent on initiation of the Phase I clinical trial for two PentaStaph antigens that target the most virulent toxins produced by the bacteria.

Learn more: Market Report -- In Play (NABI)


Share this article with your social network, just click below to share now!